What is Reapplix?
Reapplix specializes in personalized wound healing solutions, most notably through its innovative 3C Patch System. By utilizing a small sample of a patient's own blood, the system creates a concentrated, autologous patch that significantly accelerates the healing process for hard-to-heal wounds. This technology is specifically engineered to address the complex needs of patients suffering from diabetic foot ulcers, a condition that often leads to severe complications if left untreated.
The company's market position is bolstered by its alignment with international clinical guidelines, including recommendations from the International Working Group on the Diabetic Foot. By offering a cost-effective and evidence-based alternative to traditional wound care, Reapplix is effectively disrupting the standard of care, providing a scalable solution that integrates seamlessly into existing clinical workflows.
How much funding has Reapplix raised?
Reapplix has raised a total of $25.6M across 2 funding rounds:
Unspecified
$3M
Other Financing Round
$22.6M
Unspecified (2016): $3M with participation from Novo Seeds, Vækstfonden, and SEED Capital
Other Financing Round (2020): $22.6M, investors not publicly disclosed
Key Investors in Reapplix
Novo Seeds
Novo Holdings is a Danish private limited liability company wholly owned by the Novo Nordisk Foundation, focusing on long-term value creation in the life sciences sector.
Vækstfonden
Danmarks Eksport- og Investeringsfond (EIFO) serves as Denmark's common entry point for risk capital, offering equity financing to support innovative technologies and international growth.
SEED Capital
A prominent venture capital firm specializing in early-stage investments, providing the necessary resources for high-growth companies to scale their operations.
What's next for Reapplix?
With the recent capital deployment, Reapplix is expected to focus on expanding its operational footprint and accelerating the adoption of the 3C Patch System across international markets. The strategic roadmap likely includes further clinical studies to broaden the application of its regenerative technology and the strengthening of its supply chain to meet increasing demand.
As the company moves into its next phase of growth, the focus will remain on demonstrating long-term economic value to healthcare providers and payers. By maintaining its commitment to clinical excellence and patient outcomes, Reapplix is poised to become a cornerstone in the management of chronic wounds, potentially setting a new benchmark for personalized regenerative therapies in the global healthcare landscape.
